Search Results - "Grosse, Evelyn Ellis"

Refine Results
  1. 1

    The Efficacy and Safety of Tigecycline for the Treatment of Complicated Intra-Abdominal Infections: Analysis of Pooled Clinical Trial Data by Babinchak, Timothy, Grosse, Evelyn Ellis, Dartois, Nathalie, Rose, Gilbert M., Loh, Evan

    Published in Clinical infectious diseases (01-09-2005)
    “…This pooled analysis includes 2 phase 3, double-blind trials designed to evaluate the safety and efficacy of tigecycline, versus that of imipenem-cilastatin,…”
    Get full text
    Journal Article
  2. 2
  3. 3

    Pharmacokinetic-Pharmacodynamic Considerations in the Design of Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia Studies: Look before You Leap by Ambrose, Paul G., Bhavnani, Sujata M., Grosse, Evelyn J. Ellis, Drusano, George L.

    Published in Clinical infectious diseases (01-08-2010)
    “…Our thesis is a simple one: although a drug can fail in an individual patient for many reasons, appropriately sized and conducted drug-development programs…”
    Get full text
    Journal Article Conference Proceeding
  4. 4

    The Pharmacokinetic and Pharmacodynamic Profile of Tigecycline by Meagher, Alison K., Ambrose, Paul G., Grasela, Thaddeus H., Grosse, J. Ellis

    Published in Clinical infectious diseases (01-09-2005)
    “…Tigecycline, a first-in-class expanded-spectrum antimicrobial agent, has demonstrated efficacy in the treatment of complicated intra-abdominal and skin and…”
    Get full text
    Journal Article
  5. 5
  6. 6

    Frequentist and Bayesian Pharmacometric-Based Approaches To Facilitate Critically Needed New Antibiotic Development: Overcoming Lies, Damn Lies, and Statistics by Ambrose, Paul G, Hammel, Jeffrey P, Bhavnani, Sujata M, Rubino, Christopher M, Ellis-Grosse, Evelyn J, Drusano, George L

    Published in Antimicrobial Agents and Chemotherapy (01-03-2012)
    “…Antimicrobial drug development has greatly diminished due to regulatory uncertainty about the magnitude of the antibiotic treatment effect. Herein we evaluate…”
    Get full text
    Journal Article
  7. 7

    Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites by Guyader, Dominique, Patat, Alain, Ellis-Grosse, Evelyn J., Orczyk, Gayle P.

    Published in Hepatology (Baltimore, Md.) (01-11-2002)
    “…Water retention and dilutional hyponatremia, mainly attributable to an impairment of free water excretion and increased vasopressin activity, are…”
    Get full text
    Journal Article
  8. 8

    Evaluation of Activity and Emergence of Resistance of Polymyxin B and ZTI-01 (Fosfomycin for Injection) against KPC-Producing Klebsiella pneumoniae by Diep, John K, Sharma, Rajnikant, Ellis-Grosse, Evelyn J, Abboud, Cely S, Rao, Gauri G

    Published in Antimicrobial agents and chemotherapy (01-02-2018)
    “…ZTI-01 (fosfomycin for injection) is a broad-spectrum antibiotic with a novel mechanism of action and is currently under development in the United States for…”
    Get full text
    Journal Article
  9. 9
  10. 10

    Exploration of the Pharmacokinetic-Pharmacodynamic Relationships for Fosfomycin Efficacy Using an In Vitro Infection Model by VanScoy, Brian D, McCauley, Jennifer, Ellis-Grosse, Evelyn J, Okusanya, Olanrewaju O, Bhavnani, Sujata M, Forrest, Alan, Ambrose, Paul G

    Published in Antimicrobial agents and chemotherapy (01-12-2015)
    “…Fosfomycin, a phosphonic class antibiotic with a broad spectrum of antibacterial activity, has been used outside the United States since the early 1970s for…”
    Get full text
    Journal Article
  11. 11

    Pharmacodynamic and immunomodulatory effects of polymyxin B in combination with fosfomycin against KPC-2-producing Klebsiella pneumoniae by Sharma, Rajnikant, Garcia, Estefany, Diep, John K., Lee, Vince H., Minhaj, Faisal, Jermain, Brian, Ellis-Grosse, Evelyn J., Abboud, Cely S., Rao, Gauri G.

    “…•Host immunity plays an important role in clearance of bacterial infection.•Immunomodulatory and pharmacodynamic effects of polymyxin B and fosfomycin as mono-…”
    Get full text
    Journal Article
  12. 12

    Relationship between Fosfomycin Exposure and Amplification of Escherichia coli Subpopulations with Reduced Susceptibility in a Hollow-Fiber Infection Model by VanScoy, Brian, McCauley, Jennifer, Bhavnani, Sujata M, Ellis-Grosse, Evelyn J, Ambrose, Paul G

    Published in Antimicrobial agents and chemotherapy (01-09-2016)
    “…Understanding the relationship between antibiotic exposure and amplification of bacterial subpopulations with reduced drug susceptibility over time is…”
    Get full text
    Journal Article
  13. 13

    Activity of fosfomycin when tested against US contemporary bacterial isolates by Flamm, Robert K., Rhomberg, Paul R., Watters, Amy A., Sweeney, Kim, Ellis-Grosse, Evelyn J., Shortridge, Dee

    “…Fosfomycin and comparators were susceptibility tested against over 2200 contemporary clinical isolates from US medical centers. Fosfomycin was active against…”
    Get full text
    Journal Article
  14. 14

    Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose by Rodvold, Keith A., Gotfried, Mark H., Cwik, Michael, Korth-Bradley, Joan M., Dukart, Gary, Ellis-Grosse, Evelyn J.

    Published in Journal of antimicrobial chemotherapy (01-12-2006)
    “…Objectives: The purpose of this study was to determine the tissue and corresponding serum concentration of tigecycline at selected time points in gall bladder,…”
    Get full text
    Journal Article
  15. 15
  16. 16
  17. 17

    Pharmacokinetic/pharmacodynamic profile for tigecycline—a new glycylcycline antimicrobial agent by Meagher, Alison K., Ambrose, Paul G., Grasela, Thaddeus H., Ellis-Grosse, Evelyn J.

    “…Tigecycline is a new first-in-class glycylcycline antimicrobial agent with expanded broad-spectrum activity against both Gram-negative and Gram-positive…”
    Get full text
    Journal Article
  18. 18
  19. 19

    Exposure–response analyses of tigecycline tolerability in healthy subjects by Passarell, Julie, Ludwig, Elizabeth, Liolios, Kathryn, Meagher, Alison K, Grasela, Thaddeus H, Babinchak, Timothy, Ellis-Grosse, Evelyn J

    “…Abstract Tigecycline exposure (area under the concentration–time curve [AUC(0-∞) ] and maximum serum concentration [ Cmax ]) and first occurrence of nausea and…”
    Get full text
    Journal Article
  20. 20

    Moving goalposts-regulatory oversight of antibacterial drugs by Brenner, Randall, Ellis-Grosse, Evelyn J, Echols, Roger

    Published in Nature biotechnology (01-12-2006)
    “…Is uncertainty concerning the regulation of antimicrobial drug trials stifling investment in infectious disease treatments? Here, experts from a large pharma…”
    Get full text
    Journal Article